The Function of Tyrosine Hydroxylase in the Normal and Parkinsonian Brain

Author(s): Christopher Tolleson, Daniel Claassen

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 11 , Issue 4 , 2012

Become EABM
Become Reviewer
Call for Editor


Tyrosine hydroxylase (TH) is the rate limiting step in the biosynthesis of dopamine and other catecholamines. Differences have been noted in concentration and availability of this enzyme and its cofactors in disease states such as Parkinson’s disease (PD) which are subject to alterations in catecholamines. More evidence suggests in fact that TH may play a direct role in the pathogenesis of PD, especially through oxidative stress and pro-inflammatory mechanisms. Treatment for PD has classically involved maximizing endogenous dopamine by medicinal options that either replace dopamine or augment the dopaminergic pathway. The medications are unfortunately limited, given they are not curative and involve potential short-term and long-term side effects. Gene therapy in PD is a burgeoning field which provides a way to augment dopamine production, and potentially protect the dopaminergic neurons from further degeneration. Given its importance in dopamine catabolism and the possibility that it may contribute to pathogenesis, TH is one target of gene therapy. Further research into the regulatory mechanisms and function of TH are promising in improving gene therapy approaches as well as other treatment modalities.

Keywords: Gene therapy, oxidative stress, Parkinson’s disease, tyrosine hydroxylase.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 29 May, 2012
Page: [381 - 386]
Pages: 6
DOI: 10.2174/187152712800792794
Price: $65

Article Metrics

PDF: 27